Drug intelligence / Profile preview

conditioning regimen C

Development stage: Unknown
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Intravenous, External

Overview

Conditioning regimen C is a specific pre-transplant conditioning regimen utilized in allogeneic hematopoietic stem cell transplantation for children and young adults diagnosed with various blood cancers. This regimen consists of fludarabine administered intravenously, busulfan administered intravenously, and total body irradiation. It is being investigated in a phase II clinical trial (NCT03779854) as part of a strategy to prevent chronic graft-versus-host disease.

Targets

DNA

Beyond the preview

Go deeper on conditioning regimen C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on conditioning regimen C.

Explore the full profile